Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Buy” from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $46.43.

DNTH has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer upped their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Finally, Raymond James increased their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, November 8th.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after buying an additional 384,182 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Dianthus Therapeutics by 860.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after buying an additional 72,509 shares during the last quarter. HighVista Strategies LLC purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $542,000. SG Americas Securities LLC grew its stake in shares of Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after purchasing an additional 4,506 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Dianthus Therapeutics by 281.9% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock valued at $1,022,000 after purchasing an additional 29,159 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

DNTH stock opened at $24.39 on Monday. The firm has a market capitalization of $721.87 million, a PE ratio of -9.76 and a beta of 1.74. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The business has a 50 day simple moving average of $26.44 and a 200-day simple moving average of $26.53.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, equities research analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.